MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination